Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Articles

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their pharmacies through network exclusions and targeted marketing. 

Insurer-PBM Firms Dominate Medicare Part D Market, Steering Patients to Their Pharmacies

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.


Understanding gMG: Autoantibodies and Life-Altering Muscle Weakness

Mutations in one of the first human-isolated strains of H5N1 bird flu in the US were identified by the Texas Biomedical Research Institute.

New Insights Into H5N1 Variability in Human Mutations

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial. 

FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Multiple Myeloma: Enrollment of Black Patients in Trials Required for Initial FDA Approval

I apologize, but it seems there is no content provided for me to summarize and analyze. Please provide the text of the article, and I will be happy to assist you with a summary and key takeaways

To Improve Clinical Trial Equity in  Multiple Myeloma, Just Ask

Collaborating for Cancer Care Equity:  Community and Academic Insights

Elevating Value in Cancer Care With  Innovations, Accessibility, Equity

Innovating Cancer Care Through Equity and AI: Vanderbilt’s Vision

Advancing Equitable Access to Elevate  Value-Based Cancer Care

Putting Patients First by Extending  the Reach of World-Class Care

As Myeloma Trials Tackle Frontline Treatment,  Where Are the Black Patients?

Table Multiple Myeloma Trials November 2024

SPOTLIGHT: What the Approval of Isatuximab Plus VRd Means to Multiple Myeloma Care